LBT Innovations Limited

Equities

LBT

AU000000LBT8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:55:57 2024-05-15 am EDT			5-day change	1st Jan Change
0.017 ^AUD	0.00%		-5.56%	+54.55%

May. 08	Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024
Apr. 29	LBT Innovations Sells APAS Independence Instrument to NovaCina	MT

LBT Innovations : ShareCafe’s “Hidden Gems” Webinar

September 13, 2021 at 12:22 am EDT

10th Sep 2021

ShareCafe's 'Hidden Gems' Webinar

On Friday the 10th of September our Managing Director and CEO Brent Barnes presented at the ShareCafé Small Cap 'Hidden Gems' webinar. The webinar was held online as part of the regular ShareCafé Hidden Gems series focussed on micro and small cap ASX listed companies.

If you missed the presentation a recording is available below.

Attachments

Original document
Permalink

Disclaimer

LBT Innovations Ltd. published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 04:21:04 UTC.

Latest news about LBT Innovations Limited

Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024	May. 07
LBT Innovations Sells APAS Independence Instrument to NovaCina	Apr. 28	MT
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data	Mar. 13	MT
LBT Innovations' APAS PharmaQC Completes Primary Validation; Shares Up 79%	Mar. 12	MT
Transcript : LBT Innovations Limited, Q2 2024 Earnings Call, Feb 29, 2024	Feb. 28
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher	Feb. 23	MT
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
LBT Innovations Makes First Sale of APAS PharmaQC; Shares Jump 31%	Feb. 21	MT
LBT Innovations Limited Appoints Dan Hill as Non-Executive Director	Dec. 13	CI
LBT Innovations Limited Announces Retirement of Damian Lismore as Director. Effective 29 November 2023	Nov. 26	CI
LBT Innovations Secures Approval for AU$1.7 Million Loan Restructuring	Nov. 06	MT
LBT Innovations Fully Repays Share Placement Facility	23-10-12	MT
LBT Innovations Raising Up to AU$4.5 Million Via Entitlement Offer; Shares Down 27%	23-10-12	MT
LBT Innovations Secures R&D Tax Refund for Fiscal Year 2023; Shares Rally 11%	23-09-04	MT
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
LBT Innovations Flags AU$13 Million Impairment Charge	23-08-04	MT
LBT Innovations Limited Appoints Rebecca Wilson as Director	23-07-04	CI
LBT Innovations Appoints Chair; Shares Jump 7%	23-07-02	MT
LBT Innovations Limited Announces the Retirement of Simon Arkell as Non-Executive Director	23-03-29	CI
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Transcript : LBT Innovations Limited, Q2 2023 Earnings Call, Jan 25, 2023	23-01-24
LBT Innovations, AstraZeneca Partner to Develop APAS Pharma Product	23-01-09	MT
Astrazeneca Partners LBT for Apas Pharma Development	23-01-08	CI
LBT Innovations Limited Receives an Initial Purchase Order from Thermo Fisher Scientific, Inc	22-12-19	CI
LBT Innovations Subsidiary Appoints Thermo Fisher as Exclusive Distributor for Europe	22-12-18	MT

Chart LBT Innovations Limited

Duration

Period

More charts

Company Profile

LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LBT INNOVATIONS LIMITED	+54.55%	15.08M
MODERNA, INC.	+29.13%	49.18B
IQVIA HOLDINGS INC.	+0.96%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.29%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.70%	18.71B
BIO-TECHNE CORPORATION	+8.15%	13.26B
MEDPACE HOLDINGS, INC.	+32.02%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.71%	11.99B

Other Biotechnology & Medical Research